Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Asthma · Respiratory Syncytial Virus Infections

GSK Glaxo Smith

GlaxoSmithKline

GSK Glaxo Smith clinical programs — 205 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX HQ
30 Employees
NMPA registrant Type
Company details
Status
Public
HQ
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX
Employees
30
Programs
205
Drugs
194
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

GSK Glaxo Smith projects

205 ClinicalTrials.gov programs sponsored by GSK Glaxo Smith.

GSK Glaxo Smith has 205 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

205 programs

Clinical programs

Page 3 of 5

  1. 219590

    GlaxoSmithKline

    Neoplasms

    phase 2 small molecule active

    1 trial

  2. 219867

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  3. 222291

    GlaxoSmithKline

    Liver Diseases, Alcoholic

    phase 2 other active

    1 trial

  4. 222730

    GlaxoSmithKline

    Ovarian Neoplasms

    phase 2 other active

    1 trial

  5. 222892

    GlaxoSmithKline

    MMRp/ MSS colon cancer

    phase 2 small molecule active

    1 trial

  6. 223050

    GlaxoSmithKline

    Neoplasms, Prostate

    phase 2 other active

    1 trial

  7. 223559

    GlaxoSmithKline

    Tumours, Gynecological

    phase 2 small molecule active

    1 trial

  8. 223584

    GlaxoSmithKline

    Myelodysplastic Syndrome

    phase 2 other active

    1 trial

  9. 223646

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 other active

    1 trial

  10. 223675

    GlaxoSmithKline

    Gastrointestinal Neoplasms

    phase 2 other active

    1 trial

  11. 224035

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 2 other active

    1 trial

  12. 224083

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 2 small molecule active

    1 trial

  13. 224317

    GlaxoSmithKline

    Relapsed or Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  14. 300148

    GlaxoSmithKline

    Neoplasms

    phase 2 small molecule active

    1 trial

  15. 300336

    GlaxoSmithKline

    Influenza, Human

    phase 2 small molecule active

    1 trial

  16. 300356

    GlaxoSmithKline

    Influenza, Human

    phase 2 small molecule active

    1 trial

  17. Aprepitant

    GlaxoSmithKline

    Nausea and Vomiting

    phase 2 small molecule completed

    1 trial

  18. Buffer S9b Solution for suspension for injection

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 2 small molecule active

    1 trial

  19. Buffer S9b Solution for suspension for injection

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 2 small molecule active

    1 trial

  20. DTPw-HBV/Hib-MenAC conjugate vaccine

    GlaxoSmithKline

    Diphtheria

    phase 2 mab completed

    1 trial

  21. Dectova 10 mg/mL solution for infusion

    GlaxoSmithKline

    Influenza, Human

    phase 2 small molecule active

    1 trial

  22. FF/GSK573719

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  23. FF/GW642444M

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  24. Fluticasone Furoate

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  25. Fluticasone furoate (FF) (100 mcg)

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  26. Fluticasone propionate

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  27. GSK Biologicals' GSK2340274A (two different formulations)

    GlaxoSmithKline

    Influenza

    phase 2 mab completed

    1 trial

  28. GSK1070806

    GlaxoSmithKline

    Dermatitis, Atopic

    phase 2 small molecule terminated

    1 trial

  29. GSK221149A

    GlaxoSmithKline

    Obstetric Labour, Premature

    phase 2 small molecule completed

    1 trial

  30. GSK233705 12.5mcg

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  31. GSK256066

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  32. GSK3196165 Dose 1

    GlaxoSmithKline

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  33. GSK4527226

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  34. GSK962040 50 mg

    GlaxoSmithKline

    Gastroparesis

    phase 2 small molecule terminated

    2 trials

  35. GW679769

    GlaxoSmithKline

    Postoperative Nausea and Vomiting

    phase 2 small molecule completed

    1 trial

  36. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Relapsed/Refractory Tumors

    phase 2 small molecule active

    1 trial

  37. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 2 small molecule active

    1 trial

  38. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Rectal

    phase 2 small molecule active

    1 trial

  39. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 2 small molecule active

    1 trial

  40. Locally Sourced 0.9% Sodium Chloride

    GlaxoSmithKline

    Dermatitis, Atopic

    phase 2 small molecule active

    1 trial

  41. Locally Sourced 0.9% Sodium Chloride

    GlaxoSmithKline

    Dermatitis, Atopic

    phase 2 small molecule active

    1 trial

  42. NaCl 0.9% solution

    GlaxoSmithKline

    Meningitis, Meningococcal

    phase 2 small molecule active

    1 trial

  43. NaCl solution

    GlaxoSmithKline

    Herpes Simplex

    phase 2 small molecule active

    1 trial

  44. Other: Placebo

    GlaxoSmithKline

    Menopausal and Female Climacteric States

    phase 2 small molecule completed

    1 trial

  45. Placebo for GSK5784283.

    GlaxoSmithKline

    Asthma

    phase 2 small molecule active

    1 trial

  46. Placebo to Match GSK3915393 Tablet

    GlaxoSmithKline

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  47. Placebo to Match GSK3965193 Tablets

    GlaxoSmithKline

    Hepatitis B

    phase 2 small molecule active

    1 trial

  48. Reblozyl 75 mg powder for solution for injection

    GlaxoSmithKline

    Myelofibrosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does GSK Glaxo Smith have?

205 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.